Compare GCV & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCV | ADVM |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 94.6M |
| IPO Year | N/A | 2014 |
| Metric | GCV | ADVM |
|---|---|---|
| Price | $4.21 | $4.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 57.9K | ★ 373.3K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 13.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,191.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.15 | $1.78 |
| 52 Week High | $4.58 | $6.91 |
| Indicator | GCV | ADVM |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 46.81 |
| Support Level | $4.02 | $4.07 |
| Resistance Level | $4.15 | $4.23 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 79.17 | 54.35 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.